In the Nordic NEC 2 study, first‐line platinum/etoposide treatment led to a significantly shorter PFS and OS compared to first‐line temozolomide‐based treatment in patients with NET G3 with a Ki‐67 < 55%.7 This evidence concerns the gene MKI67 and neuroendocrine carcinoma.